The forecast for Brazil's insulin imports indicates a slight decline in volume over the period 2024-2028, decreasing marginally from 2.07 thousand kilograms in 2024 to 2.03 thousand kilograms in 2028. With no historical data available for 2023 in this dataset, it is assumed to provide the baseline for these forecasts.
The year-on-year variation shows a consistent yet modest decrease of approximately 0.5% each year, reflecting gradual reduction trends. Over the entire five-year forecast period, the compound annual growth rate (CAGR) suggests an average annual decrease in imports.
Future trends to monitor include potential shifts in domestic production capacity, regulatory changes affecting pharmaceutical imports, and technological advancements in biosimilar insulin. Additionally, global market price fluctuations and national healthcare policies could significantly influence future import volumes.
